ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, has announced that four abstracts, containing data from independent clinical studies, have been accepted and will be presented at the San Antonio Breast Cancer Symposium, 5 th – 9 th December 2017.
These new studies further support the value of prospective surveillance using L-Dex for the early detection of subclinical lymphoedema and subsequent reduction in chronic breast cancer related lymphoedema (BCRL) rates.
The four accepted abstracts are:
- L-Dex® surveillance of breast cancer-related lymphoedema: A retrospective study Primary author – Koelmeyer LA
- Low rates of chronic breast cancer related lymphedema (BCRL) in a cohort of high-risk patients undergoing prospective surveillance with bioimpedance spectroscopy (BIS) Primary author – Kaufman D, MD
- Utilization of BIS in the prevention of chronic breast cancer related lymphedema Primary author – Kaufman D, MD
- The impact of a structured surveillance protocol using bioimpedance spectroscopy (BIS) on preventing breast cancer related lymphedema (BCRL) in high-risk patients Primary author – Whitworth P, MD
“These studies add to the growing body of clinical evidence on how physicians are able to manage their cancer patients and limit their progression of BCRL using L-Dex. We are very pleased to continue to see that L-Dex, used in a clinical setting, has such positive impact on reducing the impact on patients of this debilitating disease,” said Richard Carreon, Managing Director and CEO of ImpediMed.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.